التفاصيل البيبلوغرافية
| العنوان: |
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. |
| المؤلفون: |
Donato, Eva M, Fernández-Zarzoso, Miguel, Hueso, Jose Antonio, de la Rubia, Javier |
| المصدر: |
OncoTargets & Therapy; Aug2018, Vol. 11, p4583-4590, 8p |
| مصطلحات موضوعية: |
HODGKIN'S disease, ANAPLASTIC thyroid cancer, LYMPHOMAS, CANCER chemotherapy, IMMUNOGLOBULINS |
| مستخلص: |
Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date. [ABSTRACT FROM AUTHOR] |
|
Copyright of OncoTargets & Therapy is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder